Aktienanalyse zu Cerus Corp (CERS)CERSCerus Corp

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Cerus Corp is a good buy right now due to its recent revenue growth and positive analyst ratings. The current price is $2.65, significantly lower than the analyst price target of $6.50, indicating a potential upside of 145%. Additionally, the company reported a 5.3% year-over-year increase in revenue to $63.3 million, surpassing expectations, which suggests improving market demand for its products. However, the main risk is the negative earnings per share (EPS) of -$0.01, which reflects ongoing losses.

3 analysts cover CERS: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.50.